https://orcid.org/0000-0002-3485-0850
References
- ACOG Practice Bulletin 226. Screening for Fetal Chromosomal Abnormalities. September 2020.
- SMFM Consult Series #42. The role of ultrasound in women who undergo cfDNA screening. March 2017.
- Gregg AR, Skotko BG, Benkendorf JL, et al. Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics. Genet Med. 2016;18(10):1056–1065.
- Nussbaum RL, McInnes RR, Willard HF. Principles of clinical cytogenetics and genome analysis. In: Thompson & Thompson genetics in medicine. 8th ed. Philadelphia, PA: Elsevier; 2016. p.57–74.
- Gil MM, Accurti V, Santacruz B, et al. Analysis of cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol. 2017;50(3):302–314.
- Kagan KO, Wright D, Maiz N, et al. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol. 2008;32(4):488–492.
- Alamillo CM, Krantz D, Evans M, et al. Nearly a third of abnormalities found after first-trimester screening are different than expected: 10-year experience from a single center. Prenat Diagn. 2013;33(3):251–256.
- Nicolaides KH, Heath V, Cicero S. Increased fetal nuchal translucency at 11–14 weeks. Prenat Diagn. 2002;22(4):308–315.
- Nicolaides KH, Azar G, Byrne D, et al. Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. BMJ. 1992;304(6831):867–869.
- Scholl J, Durfee SM, Russell MA, et al. First trimester cystic hygroma: relationship of nuchal translucency thickness and outcomes. Obstet Gynecol. 2012;120(3):551–559.
- Morris RK, Bilagi A, Devani P, et al. Association of serum PAPP-A levels in first trimester with small for gestational age and adverse pregnancy outcomes: systematic review and meta-analysis. Prenat Diagn. 2017;37(3):253–265.
- Indications for outpatient antenatal fetal surveillance: ACOG committee opinion summary, number 828. Obstet Gynecol. 2021;137(6):1148–1151.
- Sirikunalai P, Wanapirak C, Sirichotiyakul S, et al. Associations between maternal serum free beta human chorionic gonadotropin (β-hCG) levels and adverse pregnancy outcomes. J Obstet Gynaecol. 2016;36(2):178–182.
- Krantz D, Goetzl L, Simpson JL, et al. First trimester maternal serum biochemistry and fetal nuchal translucency screening (BUN) study group. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol. 2004;191(4):1452–1458.
- Spencer K, Yu CK, Cowans NJ, et al. Prediction of pregnancy complications by first-trimester maternal serum PAPP-A and free beta-hCG and with second-trimester uterine artery Doppler. Prenat Diagn. 2005;25(10):949–953.
- Perni SC, Predanic M, Cox K, et al. The association between first-trimester levels of PAPP-A and perinatal complications. Am J of Obstet Gynecol. 2004;191(6):S78.
- Hyett JA, Perdu M, Sharland GK, et al. Increased nuchal translucency at 10-14 weeks of gestation as a marker for major cardiac defects. Ultrasound Obstet Gynecol. 1997;10(4):242–246.
- Bilardo CM, Müller MA, Pajkrt E, et al. Increased nuchal translucency thickness and normal karyotype: time for parental reassurance. Ultrasound Obstet Gynecol. 2007;30(1):11–18.
- Baer RJ, Norton ME, Shaw GM, et al. Risk of selected structural abnormalities in infants after increased nuchal translucency measurement. Am J Obstet Gynecol. 2014;211:675.e1–19.
- Dugoff L, Hobbins JC, Malone FD, et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER trial). Am J Obstet Gynecol. 2004;191(4):1446–1451.
- Ong CY, Liao AW, Spencer K, et al. First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein a as predictors of pregnancy complications. BJOG. 2000;107(10):1265–1270.
- Barrett SL, Bower C, Hadlow NC. Use of the combined first-trimester screen result and low PAPP-A to predict risk of adverse fetal outcomes. Prenat Diagn. 2008;28(1):28–35.
- Norton ME, Jelliffe-Pawlowski LL, Currier RJ. Chromosome abnormalities detected by current prenatal screening and noninvasive prenatal testing. Obstet Gynecol. 2014;124(5):979–986.